Update on treatment of polymyalgia rheumatica
Submitted: 17 August 2017
Accepted: 8 February 2018
Published: 27 March 2018
Accepted: 8 February 2018
Abstract Views: 5423
PDF: 3234
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Similar Articles
- A. Ciocci, L. Buratti, G. Coari, M. Di Franco, A.M. Iagnocco, M.T. Mauceri, A. Serio, Rheumatoid arthritis: frequency of hospitalization and evaluation of economic burden , Reumatismo: Vol. 53 No. 3 (2001)
- L. Fioravante da Silveira, A. Zago, D. Zanchet, D. Chemello, Macrophage activation syndrome in a patient with systemic lupus erythematosus undergoing cyclophosphamide treatment: a case report , Reumatismo: Vol. 75 No. 2 (2023)
- V. Bruzzese, P. Scolieri, J. Pepe, Efficacy of gluten-free diet in patients with rheumatoid arthritis , Reumatismo: Vol. 72 No. 4 (2020)
- F. Salaffi, C.M. Vaccaro, T. Manacorda, L. Pardini, V. Coletta, C. Montecucco, Health-related quality of life in patients with rheumatoid arthritis: assessment by a Italian version of the Arthritis Impact Measurement Scales, Version 2 (AIMS2) , Reumatismo: Vol. 62 No. 1 (2010)
- M. Vadacca, F. Buzzulini, A. Rigon, G. Coppolino, A. Palma Modoni, R. Massa, A. Afeltra, Neuropsychiatric Lupus Erythematosus , Reumatismo: Vol. 58 No. 3 (2006)
- A. Cauli, G. Porru, A. Vacca, A. Mameli, V. Ibba, V. Mura, M. Piga, A. Mathieu, IFN-αα induced psoriatic arthritis and HCV-related liver cirrhosis. Therapeutic options and patient’s opinion , Reumatismo: Vol. 60 No. 1 (2008)
- Z. Morel, R. Suarez, E. Avalos, S. Velázquez, F. Martínez, V. Lezcano, N. Astigarraga, C. Ghezzi, S. Brizuela, G. Samudio, Multisystemic inflammatory syndrome related to COVID-19, with latent tuberculosis in bone marrow, and satisfactory response to tocilizumab, in a 7-year-old boy , Reumatismo: Vol. 73 No. 4 (2021)
- M. Tasso, N. Bertolini, E. Mostacciuolo, S. Passavanti, J.M.E. Luppino, A. Del Puente, R. Peluso, F. Santelli, R. Scarpa, L. Costa, F. Caso, Effectiveness and safety profile of tofacitinib and baricitinib in rheumatoid arthritis patients: results from a 24-month real-life prospective study in Southern-Italy , Reumatismo: Vol. 74 No. 3 (2022)
- F.M. Mariani, A. Alunno, F. Carubbi, C. Ferri, A rare case of symptomatic creatine kinase elevation in a patient with rheumatoid arthritis treated with baricitinib , Reumatismo: Vol. 76 No. 2 (2024)
- V. Riccieri, A. Spadaro, E. Taccari, A. Zoppini, I. Markus, M. Sesztak, J. Ortutay, E. Koo, Immunohistochemical analysis of the expression of main adhesion molecules and tumor necrosis factors in the synovial membrane of psoriatic arthritis , Reumatismo: Vol. 55 No. 3 (2003)
<< < 37 38 39 40 41 42 43 44 45 46 > >>
You may also start an advanced similarity search for this article.